Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options.

Simonsson, B

Treatment of minimal residual disease in acute myelogenous leukemia (AML): focus on immunotherapeutic options. [electronic resource] - Leukemia Jun 1996 - s44-5 p. digital

Publication Type: Editorial

0887-6924


Adjuvants, Immunologic--therapeutic use
Antibodies, Monoclonal--therapeutic use
Graft vs Host Disease--immunology
Humans
Hydroxyquinolines--therapeutic use
Immunotherapy--methods
Interleukin-2--therapeutic use
Leukemia, Myeloid, Acute--therapy
Leukocyte Transfusion
Neoplasm, Residual